The hope is that we were far enough along with the PDD trial to have robust reportable, if not submittable, data. If patients and PIs perceive therapeutic effect, I wonder how much pressure they can bring to bear on the trial clinics to continue with treatment under some kind of accommodation protocol (remote visit, tele-assessment, interim cancel, etc.) In-patient facilities (hospitals) will have their hands full right now, but not out-patient.
We'll see.
Market Data 
Markets 
AI
